Alto neuroscience announces plans to accelerate development of alto-207 in treatment resistant depression following successful outcome from recent fda meeting

Mountain view, calif.--(business wire)---- $anro #cns--alto neuroscience, inc. (“alto”) (nyse: anro), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, announced today that, following a successful outcome from a recent fda meeting, it plans to accelerate the development of alto-207 for people with treatment resistant depression (trd). the $50 million private placement announced today supports expanded development of alto-207, and.
ALTO Ratings Summary
ALTO Quant Ranking